Jul 24, 09:07
100% of moneycontrol users recommend buying Cadila Health.
What's your call on Cadila Health today?
Read 3 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2713.95||-0.73||2939.80||2140.35||46,228.08|
|Mar' 14||Dec' 13||Sep' 13||Jun' 13|
|Scheme||No. of Shares|
|Reliance Pharma Fund (G)||753,552|
|Franklin India Bluechip Fund (G)||667,058|
|Reliance Equity Opportunities Fund - Retail Plan (G)||623,194|
|SBI Magnum Tax Gain Scheme (G)||558,019|
Vaibhav Global Recommended on Jun 11th 2014
Recommended price 675.00 | Peak from reco 910.00 34.81%
What are Multi baggers?
Our experts panel will help you to get you those life-changing stocks, tomorrow's bluechips today.
Cadila Health is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 22,419.96 crore.The company has reported a consolidated sales of Rs 1,916.33 crore and a Net Profit of Rs 246.42 crore for the quarter ended Mar 2014.
The company management includes Pankaj R Patel - Chairman & Managing Director, Sharvil P Patel - Deputy Managing Director, Humayun Dhanrajgir - Director, Mukesh M Patel - Director, Nitin R Desai - Director, Apurva S Diwanji - Director, Dharmishta N Rawal - Additional Director.
It is listed on the BSE with a BSE Code of 532321 and the NSE with an NSE Code of CADILAHC.
Its Registered office is at "Zydus Tower", Satellite Cross Roads,,Sarkhej Gandhinagar Highway Ahmedabad,Gujarat - 380015.
Their Registrars are Sharepro Services (India) Pvt.Ltd.